Tailoring adjunct treatments accordingly—such as CXCR2 inhibitors for NASH-HCC neutrophils [28] and antiviral therapy for HBV-HCC [99]—will be crucial for maximizing the effectiveness of trained immunity approaches. This evidence concerns the gene CXCR2 and hepatocellular carcinoma.